Vectura, a public UK-based emerging pharmaceutical company specialized in the application of particle science to drug delivery particularly pulmonary, oral and dermal. Vectura’s strategy is to combine proprietary pulmonary formulation and device technologies with existing, off-patent drugs either for use in new indications or for a new route of administration. Vectura’s key technology system is PowderHale™, a proprietary dry powder inhaled formulation system.